|
Table 1.1. Age-Adjusted SEER Incidence Rates and Trends for the
15 Most Common Cancers by Sex, 1992–2002
Table 1.2. A Selection of Agents Targeting Her Signaling,
All of Which Are Being Evaluated in Multiple Clinical Trials for
Various BreastCancer Indications
Table 2.1. Select List of Promising Small Molecule Inhibitors
in Development
Table 2.2. Oncology Monoclonal Antibodies on the Market, Ranked
by Date of Approval
Table 2.3. Select List of Immunotherapeutics Currently in Development,
Recognized by Financial Analysts as Promising
Table 3.1. Detection Methods Typically Used in “Cancer
Gene” Discovery
Table 3.2. Select List of Cancer-Associated Kinase Genes
Table 3.3. Select List of Cancer-Associated Phosphate Genes
Figure 1.1. Accelerated Oncogenomic Advances Made Possible by
Completion of the Human Genome Project
Figure 4.1. 2-to-1 Clinical Trial Design
Figure 4.2. 3-versus-1 Clinical Trial Design
Figure 4.3. “Simple” Clinical Trial Design
| 
